270 related articles for article (PubMed ID: 15639697)
21. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.
Torimoto K; Okada Y; Mori H; Hajime M; Tanaka K; Kurozumi A; Narisawa M; Yamamoto S; Arao T; Matsuoka H; Inokuchi N; Tanaka Y
Lipids Health Dis; 2013 Sep; 12():137. PubMed ID: 24053480
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Jones PH; Davidson MH; Kashyap ML; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
[TBL] [Abstract][Full Text] [Related]
23. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW;
Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
[TBL] [Abstract][Full Text] [Related]
24. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Zhu JR; Tomlinson B; Ro YM; Sim KH; Lee YT; Sriratanasathavorn C
Curr Med Res Opin; 2007 Dec; 23(12):3055-68. PubMed ID: 18196620
[TBL] [Abstract][Full Text] [Related]
25. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
26. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial.
Hong SJ; Jeong HS; Ahn JC; Cha DH; Won KH; Kim W; Cho SK; Kim SY; Yoo BS; Sung KC; Rha SW; Shin JH; Han KR; Chung WS; Hyon MS; Lee HC; Bae JH; Rhee MY; Kwan J; Jeon DW; Yoo KD; Kim HS
Clin Ther; 2018 Feb; 40(2):226-241.e4. PubMed ID: 29402522
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F;
Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
Robinson JG; Colhoun HM; Bays HE; Jones PH; Du Y; Hanotin C; Donahue S
Clin Cardiol; 2014 Oct; 37(10):597-604. PubMed ID: 25269777
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of rosuvastatin in Taiwanese patients.
Chiang CE; Huang SS; Sung SH
J Chin Med Assoc; 2008 Mar; 71(3):113-8. PubMed ID: 18364261
[TBL] [Abstract][Full Text] [Related]
30. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
31. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
Lloret R; Ycas J; Stein M; Haffner S;
Am J Cardiol; 2006 Sep; 98(6):768-73. PubMed ID: 16950182
[TBL] [Abstract][Full Text] [Related]
32. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
[TBL] [Abstract][Full Text] [Related]
34. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Saku K; Zhang B; Noda K;
Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906
[TBL] [Abstract][Full Text] [Related]
35. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
Deedwania PC; Gupta M; Stein M; Ycas J; Gold A;
Am J Cardiol; 2007 Jun; 99(11):1538-43. PubMed ID: 17531577
[TBL] [Abstract][Full Text] [Related]
36. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
37. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
[TBL] [Abstract][Full Text] [Related]
39. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
Olsson AG; McTaggart F; Raza A
Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A
Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
